We'll do without a biopsy
The University of East Anglia has developed a method of urine analysis called PUR (prostate urine risk), which determines the presence of a malignant prostate tumor as accurately as possible.
Scientists examined gene expression in urine samples of 535 men and found cell-free expression in 167 different genes. Then a combination of 35 genes was mistaken for biomarkers, the presence of which indicates the development of prostate cancer. The PUR test not only detects the presence of malignant neoplasms before other methods, but also helps to distribute people into different risk groups so that doctors can decide whether to do a biopsy or start treatment immediately.
If this test had existed earlier, a large number of men could have avoided unnecessary biopsy, which today is the only absolutely accurate method of diagnosing prostate cancer. Currently, the "gold standard" is a finger rectal examination, a blood test for prostate specific antigen (PSA) and ultrasound of the prostate gland, the results of which are used to determine the need for a biopsy. Unfortunately, it is not always possible to detect prostate cancer in the early stages.
According to the American Cancer Society (ACS), every 9 men get prostate cancer. Apart from skin cancer, prostate cancer is considered the most common cancer among men. ACS estimates that there will be about 174,000 new cases of prostate cancer and more than 31,000 deaths from the disease in 2019. Fortunately, the overall survival rate is quite high and is 98%, subject to early diagnosis. Since such a tumor develops rather slowly, with the help of new methods of analysis, it can be detected long before it begins to spread to the surrounding tissues.
Article by Connell et al. A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer is published in the journal BJU International.
Elena Panasyuk, portal "Eternal youth" http://vechnayamolodost.ru / based on Medical News Today: Urine test can help diagnose aggressive prostate cancer.